← Leaderboards
Daniel J Weisdorf
University Of Minnesota Twin Cities
$29,176,401
Attributed
$46,697,630
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$46,697,630 · 10
By mechanism
UL1$34,856,254 · 1
P01$8,967,086 · 4
U01$1,750,308 · 1
U10$930,915 · 1
UG1$184,800 · 1
M01$8,267 · 2
Top collaborators
- Bruce R. Blazar7 shared
- Milton Eder1 shared
- Steve G Johnson1 shared
- Sheila Riggs1 shared
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Bruce K Walcheck$7,595,159
- David A Bernlohr$13,927,503
- John W Osborn$15,454,139
- Dan S Kaufman$9,522,879
- Allison Hubel$5,868,733
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsTransplantationRelapseBaseUniversitiesEnrollmentAllogenicComplexFundingProgramsInfectionImmuneSiteMinnesotaReconstitutionProtocols DocumentationGraft-Vs-Host DiseaseNatural Killer CellsSuccessToxic EffectInfusion ProceduresReceptorClinical ResearchArea
Grant awards (46)
Off-The-Shelf Dual Targeted NK Cells For NHL$359,065
P01 · FY2024 · CA · contact PI
Off-The-Shelf Dual Targeted NK Cells For NHL$381,799
P01 · FY2023 · CA · contact PI
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$5,778,038
UL1 · FY2022 · TR
Off-The-Shelf Dual Targeted NK Cells For NHL$371,747
P01 · FY2022 · CA · contact PI
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$5,778,038
UL1 · FY2021 · TR
Off-The-Shelf Dual Targeted NK Cells For NHL$294,004
P01 · FY2021 · CA · contact PI
ALT-803 (IL-15/IL-15Rα-Fc) maintenance after allogeneic transplantation for AML$184,800
UG1 · FY2021 · HL · contact PI
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$6,970,194
UL1 · FY2020 · TR
Clinical Trials Exploiting NK Cell Activity$566,011
P01 · FY2020 · CA · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$99,921
UL1 · FY2020 · TR
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$7,421,546
UL1 · FY2019 · TR
Clinical Trials Exploiting NK Cell Activity$550,601
P01 · FY2019 · CA · contact PI
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$398,904
UL1 · FY2019 · TR
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$8,249,907
UL1 · FY2018 · TR
Clinical Trials Exploiting NK Cell Activity$546,585
P01 · FY2018 · CA · contact PI
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$159,706
UL1 · FY2018 · TR
Clinical Trials Exploiting NK Cell Activity$247,145
P01 · FY2017 · CA · contact PI
Clinical Trials Exploiting NK Cell Activity$617,975
P01 · FY2016 · CA · contact PI
Enhancing the Safety of Allogeneic Transplantation$156,285
U10 · FY2016 · HL · contact PI
Enhancing the Safety of Allogeneic Transplantation$156,285
U10 · FY2015 · HL · contact PI
Clinical Transplantation Exploiting NK Cell Activity$474,779
P01 · FY2014 · CA · contact PI
Enhancing the Safety of Allogeneic Transplantation$156,285
U10 · FY2014 · HL · contact PI
Clinical Transplantation Exploiting NK Cell Activity$461,157
P01 · FY2013 · CA · contact PI
Enhancing the Safety of Allogeneic Transplantation$156,285
U10 · FY2013 · HL · contact PI
Clinical Transplantation Exploiting NK Cell Activity$476,560
P01 · FY2012 · CA · contact PI
Enhancing the Safety of Allogeneic Transplantation$156,285
U10 · FY2012 · HL · contact PI
Clinical Transplantation Exploiting NK Cell Activity$421,429
P01 · FY2011 · CA · contact PI
Enhancing the Safety of Allogeneic Transplantation$149,490
U10 · FY2011 · HL · contact PI
Clinical Transplantation Exploiting NK Cell Activity$385,174
P01 · FY2010 · CA · contact PI
Enhanced GVHD Prophylaxis in Allogeneic Stem Cell Transplantation$169,397
U01 · FY2010 · HL · contact PI
Clinical Transplantation Exploiting NK Cell Activity$624,666
P01 · FY2009 · CA · contact PI
Enhanced GVHD Prophylaxis in Allogeneic Stem Cell Transplantation$60,908
U01 · FY2009 · HL · contact PI
Clinical Transplantation Exploiting NK Cell Activity$616,361
P01 · FY2008 · CA · contact PI
Enhanced GVHD Prophylaxis in Allogeneic Stem Cell Transplantation$1
U01 · FY2008 · HL · contact PI
Clinical Transplantation Exploiting NK Cell Activity$614,359
P01 · FY2007 · CA · contact PI
MT2003-23:NON-MYELOBLATIVE HAPLOIDENTICAL HSCT WITH NK CELL INFUSIONS IN HIGH RI$3,479
M01 · FY2007 · RR · contact PI
Enhanced GVHD Prophylaxis in Allogeneic Stem Cell Transplantation$1
U01 · FY2007 · HL · contact PI
Clinical Transplantation Exploiting NK Cell Activity$474,446
P01 · FY2006 · CA · contact PI
Enhanced GVHD Prophylaxis in Allogeneic Stem Cell Transplantation$155,000
U01 · FY2006 · HL · contact PI
NON-MYELOBLATIVE HAPLOIDENTICAL HSCT WITH NK CELL INFUSIONS IN HIGH RISK MYELOID$4,788
M01 · FY2006 · RR · contact PI
Clinical Transplantation Exploiting NK Cell Activity$483,223
P01 · FY2005 · CA
Enhanced GVHD Prophylaxis in Allogeneic Stem Cell Trans*$1
U01 · FY2005 · HL
Enhanced GVHD Prophylaxis in Allogeneic Stem Cell Trans*$405,000
U01 · FY2004 · HL
Enhanced GVHD Prophylaxis in Allogeneic Stem Cell Trans*$405,000
U01 · FY2003 · HL
Enhanced GVHD Prophylaxis in Allogeneic Stem Cell Trans*$150,000
U01 · FY2002 · HL
Enhanced GVHD Prophylaxis an Allogenein Stem Cell Trans*$405,000
U01 · FY2001 · HL